Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access

AGENUS INC

2025-Q3 EPS reported $0.37 vs consensus $2.02 ▼ miss (-81.7%)

France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.
BOT/BAL shows 42% two-year OS, 20.9-month median OS in 123 heavily pretreated MSS mCRC patients.
Phase 3 BATTMAN trial initiated Q4 2025 across 100+ sites in Canada, France, Australia, NZ.
MiNK deconsolidation generates ~$100.9M gain; net income for Q3 and nine-month periods.
Zydus provides $10M bridge facility ahead of $91M closing; equity at $7.50/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.